Pinewood Healthcare
With over 30 years manufacturing healthcare products in Ireland, Pinewood Healthcare is one of the largest generic companies with a workforce of over 340 people.
With over 30 years manufacturing healthcare products in Ireland, Pinewood Healthcare is one of the largest generic companies with a workforce of over 340 people. We are a widely diversified pharmaceutical group and market our products in over 30 countries across the globe. Pinewood Healthcare also markets and distributes branded generics to retail pharmacies and hospitals throughout Ireland.Pinewood Healthcare can offer contract manufacturing and packaging in the following areas: Oral Liquid and Suspensions, Glass, HDPE, Pet, Sachets, Cream and Ointments, Tubes and tubs (plastic and Aluminium), Non- Penicillin Powders, Glass, HDPE, Sachets.
Our manufacturing site in Tipperary has internationally recognised quality standards- ISO9001 and the CE mark which reflects the high standards maintained in Pinewood, at all times manufacturing in a GMP environment. Continuous investment on a purpose built site has created one of the most sophisticated and state of the art factories of its type in Europe.
Our promise is to offer quality products, competitively priced, delivered on time and backed by individual customer service, technical advice and marketing support.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
